CTRI/2024/03/063854尚未招募4 期
5- FLUOROURACIL AS A NOVEL ADJUNCTIVE THERAPY FOR CONSERVATIVE MANAGEMENT OF ODONTOGENIC KERATOCYST – A RANDOMIZED CONTROL TRIA
Dr Priyanka Shetty0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) All the histopathologically diagnosed cases of Odontogenic Keratocyst reporting in OPD.
- •2) All patients willing and fit for surgery.
- •3) All the cases who are undergoing treatment for the 1st time as well as the recurrent cases
排除标准
- •1) Patients with diagnoses other than Odontogenic Keratocyst reporting in OPD
- •2) Patients unwilling and unfit for surgery.
- •3) Patients who are lost to follow up.
研究者
相似试验
尚未招募
4 期
ocal application of drug 5- FLUOROURACIL as a Medication THERAPY following removal of tumour called AMELOBLASTOMACTRI/2024/03/064106Dr Priyanka Shetty
进行中（未招募）
1 期
Combination therapy of 5-Fluorouracil and Calcipotriol versus 5-Fluorouracil in the treatment of Actinic Keratosis: a multicentre randomized controlled clinical trialActinic KeratosisCTIS2024-511409-42-00niversity Hospital Maastricht232
已完成
不适用
A randomised trial of infusional 5-fluorouracil and concomitant radiotherapy in locally advanced rectal cancer, comparing three and six months of infusional 5-fluorouracilCancer of rectumCancerISRCTN93845533The Royal Marsden NHS Foundation Trust (UK)
进行中（未招募）
不适用
Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. - Nordic VIIPatient with metastatic colorectal cancer.EUCTR2005-000117-34-ISThe Nordic Colorectal Cancer Biomodulation Group550
进行中（未招募）
不适用
Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. - Nordic VIIPatient with metastatic colorectal cancer.EUCTR2005-000117-34-DKThe Nordic Colorectal Cancer Biomodulation Group550